Literature DB >> 15182041

[Standards and perspectives in locoregional hyperthermia].

Bert Hildebrandt1, Beate Rau, Johanna Gellermann, Thoralf Kerner, Annett Nicolaou, Jens-Uwe Blohmer, Ralf Ulrich Trappe, Hanno Riess, Peter Wust.   

Abstract

The term "hyperthermia" summarises different procedures of raising the temperature of a tumour-loaded tissue to a temperature of 40-43 degrees C. In this context, locoregional procedures (radiative/capacitive local, interstitial and regional hyperthermia; endoluminal hyperthermia), hyperthermic perfusion techniques (hyperthermic peritoneal and isolated limb perfusion), and whole-body hyperthermia differ with regard to their indication, expenditure of application, and evidence of efficacy. All hyperthermia techniques have in common that they have no sufficient antineoplastic activity alone in the temperature range below 43-45 degrees C, but act in a synergistic way with radiotherapy and certain cytotoxic drugs. 14 out of 18 published randomised trials on hyperthermia as an adjunct to standard radio- or chemotherapy refer to locoregional approaches. Particular progress has been made in regional radiofrequency hyperthermia, where novel multiantenna-applicators and their integration into MR-applicators ("hybrid-systems") have recently been introduced into clinical practice. In addition, combinations of hyperthermia with novel technologies (magnetic fluid hyperthermia, thermosensitive liposomes, immunotherapy, gene targeting) are imminent. We here give a critical update on the proven indications of the different locoregional hyperthermia approaches and on the current clinical and technological progress in this field.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182041     DOI: 10.1007/s10354-004-0050-7

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  1 in total

1.  Magnetic fluid hyperthermia induced by radiofrequency capacitive field for the treatment of transplanted subcutaneous tumors in rats.

Authors:  Xu-Hong Li; Peng-Fei Rong; He-Kun Jin; Wei Wang; Jin-Tian Tang
Journal:  Exp Ther Med       Date:  2011-11-30       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.